1. P354: REAL-WORLD ANALYSIS OF THE RISKS OF THROMBOTIC AND BLEEDING EVENTS IN PATIENTS RECEIVING PEGYLATED ASPARAGINASE FOR TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. (23rd June 2022) Authors: Mautner, B.; Brewer, B.; Mort, J.; Pierce, E.; Ghamsari, F.; Dibenedetto, S.; Morse, E.; Wells, L.; Morris, A.; Allen, C.; Patel, I.; D'Souza, D.; Jackson, C.; Perciavalle, M.; Yelvington, B.; Miller, R.; Abernathy, K.; Walsh, K.; Wolfe, H.; Locke, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P526: REAL-WORLD COMPARISON OF DIFFERENT TREATMENT MODALITIES FOR FAVORABLE RISK ACUTE MYELOID LEUKEMIA: STANDARD DOSE ANTHRACYCLINE VS HIGH DOSE ANTHRACYCLINE VS ADDITION OF GEMTUZUMAB OZOGAMICIN. (23rd June 2022) Authors: Mort, J.; Brewer, B.; Mautner, B.; Dibenedetto, S.; Pierce, E.; Morse, E.; Wells, L.; Ghamsari, F.; Morris, A.; Clark, S.; Reid, J.; Patel, I.; Jackson, C.; Perciavalle, M.; Yelvington, B.; Miller, R.; Abernathy, K.; Wolfe, H.; Locke, S.; Zeidner, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗